摘要
目的 探讨缺氧诱导因子 1α(hypoxiainduciblefactor 1α ,HIF 1α)在卵巢癌组织中的表达及其与血管生成的关系。方法 联合应用组织芯片和原位杂交、免疫组化技术 ,检测 2 95份卵巢上皮性肿瘤 (其中卵巢癌 2 38份、交界性卵巢肿瘤 19份、良性卵巢肿瘤 38份 )及 13份正常卵巢组织中HIF 1αmRNA和血管内皮生长因子 (VEGF)的表达情况 ,以CD3 4 单克隆抗体标记血管内皮细胞来检测微血管密度 (MVD)。结果 卵巢癌、交界性卵巢肿瘤和良性卵巢肿瘤、正常卵巢组织中HIF 1αmRNA的阳性表达率分别为 81 9%、4 2 1%、13 2 %和 0。交界性卵巢肿瘤和卵巢癌组织中HIF 1αmRNA的表达高于正常卵巢和良性卵巢肿瘤 ,卵巢癌高于交界性肿瘤 ,差异均有统计学意义 (P <0 0 1)。卵巢癌组织中HIF 1αmRNA的表达与手术病理分期和病理类型无关 (P >0 0 5 ) ,而与病理分级呈正相关 (r=0 2 4 6 ,P <0 0 1)。卵巢癌组织中HIF 1αmRNA表达与VEGF表达 (r =0 2 0 6 ,P =0 0 1)和MVD计数 (r =0 4 5 1,P <0 0 1)均呈显著正相关。结论 卵巢癌组织过度表达HIF 1αmRNA ,并通过诱导VEGF促进肿瘤的新生血管形成。
Objective To study the relation between the expression of hypoxia inducible factor 1α(HIF 1α)and angiogenesis in ovarian cancer Methods The expressions of HIF 1α mRNA, vascular endothelial growth factor(VEGF),and CD 34 in 295 patients with epithelial ovarian tumors were analyzed by tissue microarray technology, in situ hybridization and immunohistochemistry, and compared with those of 13 normal ovarian tissue samples Results The expressions of HIF 1α mRNA were observed in 0, 13 2%, 42 1% and 81 9% of normal ovarian tissue, benign, borderline and malignant ovarian tumors respectively Expression rates of HIF 1α mRNA in borderline and invasive tumors were significantly higher than those in normal ovarian tissues and benign tumors ( P <0 01) Statistical analysis revealed that the expression of HIF 1α mRNA was not related to surgical stages and histological subtypes Close positive relation was observed between the expression of HIF 1α mRNA and tumor histological grade( r =0 246, P <0 01) There were significant correlations between the expression of HIF 1α mRNA and VEGF( r = 0 206, P =0 01) and microvessel density (MVD) level( r =0 451, P <0 01) Conclusion HIF 1α may play a role in angiogenesis of ovarian carcinoma, and may promote the development of the carcinoma
出处
《中华妇产科杂志》
CAS
CSCD
北大核心
2005年第1期38-41,共4页
Chinese Journal of Obstetrics and Gynecology
基金
国家教委博士点基金资助项目 (2 0 0 0 0 63 0 13 )
关键词
组织芯片技术
卵巢癌
肿瘤组织
缺氧诱导因子1Α
血管生成
Oligonucleotide array sequence analysis
Ovarian neoplasms
Nuclear proteins
DNA binding proteins
Neorascularization, pathologic
Immunohistochemistry
